Quantitative CT in Progressive Pulmonary Fibrosis: Clinical Utility and Meaningful Threshold Definition.
Authors
Affiliations (5)
Affiliations (5)
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: [email protected].
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: [email protected].
Abstract
While quantitative CT (QCT) offers objective evaluation of radiologic progression in non-idiopathic pulmonary fibrosis (IPF) fibrosing interstitial lung disease (ILD), clinically meaningful thresholds for defining progressive pulmonary fibrosis (PPF) remain unclear. What are the minimal clinically important differences (MCIDs) in quantitative CT-based fibrosis score changes (ΔFS) over 1 year and 6 months, and do these thresholds predict outcomes and enhance risk stratification in defining PPF among patients with non-IPF fibrosing ILD? This retrospective study included patients with non-IPF fibrosing ILD who underwent volumetric CT scans at baseline and 1-year follow-up. FS was calculated using a deep learning-based QCT algorithm. The MCID for ΔFS was determined using anchor-based methods, referencing absolute 1-year forced vital capacity (FVC) change. The association of ΔFS-MCID with transplant-free survival (TFS) and its alignment with PPF criteria were analyzed using Cox regression. Concordance between QCT-based and visual assessments was also assessed. Among 476 patients, the 1-year and 6-month MCIDs were 2.24% and 1.34%, respectively. Exceeding the 1-year MCID was independently associated with poorer TFS (adjusted HR, 3.01; 95% CI: 2.19-4.14). QCT-based progression provided additional risk stratification in patients with discordant PPF criteria, including those with disagreement on visual progression (P = 0.02). Patients with both visual and QCT-based progression had worse outcomes than those with visual progression alone (P < 0.001). ΔFS above the 6-month MCID was also associated with increased mortality (adjusted HR, 2.82; 95% CI: 1.57-5.04). QCT-based PPF definition using 1-year ΔFS was prognostic across non-IPF fibrosing ILDs and enhanced risk stratification in patients with discordant PPF assessments.